β-D-Glucopyranosiduronic acid, 2-amino-4-(hydroxymethyl)phenyl, methyl ester, 2,3,4-triacetate CAS:229977-57-5 is a β-glucuronic acid-based enzymatic cleavable linker. It is developed in an extension of the peptide-based linker strategies to provide high ADC stability. Facile release of the active drug can be achieved through cleavage of the b-glucuronide glycosidic bond by the lysosomal enzyme b-glucuronidase (GUSB).
β-glucuronidases, found exclusively in the lysosomal compartment of the cell, are a class of hydrolytic lysosomal enzymes that degrade β-glucuronic acid residues into polysaccharides. They work under hydrophilic environments to release payloads from conjugates. Water-soluble β-glucosidic acid linkers are stable in plasma and efficiently deliver drugs to target cells with potent activity comparable to that of free cytotoxic drugs. β-glucosidic acid linkers can be used to couple a variety of small molecules, peptides, proteins, or other biomolecules in a series of oligonucleotides to deliver different cytotoxic drugs.
The β-glucuronide linker has various advantages, including:
- Controlled release
The β-glucuronide linker allows for controlled cleavage of the linker at the target site via its specific release mechanism. By cleaving the β-glucuronide bond, the payload is released at the desired site. This controlled release mechanism enhances therapeutic efficacy and reduces off-target effects of the payload.
- Enhanced stability
The β-glucuronide linker provides stability to various drug conjugates. For example, the linker protects the oligonucleotide from nuclease degradation during during blood circulation and ensures extended half-life and increased bioavailability of the coupling payload.
- Enhanced drug delivery
β-glucuronide linkers enable targeted delivery of therapeutic payloads to specific tissues or cells. By concatenating oligonucleotides with the β-glucuronide linker, the payload can be selectively released at the target site, thereby increasing the therapeutic index and minimizing systemic side effects.
AxisPharm maintains large selection of glucuronide linkers and provides custom synthesis and bioconjugation services to utilize this target specific enzymatic release mechanism for ADC research.
Ref. https://en.wikipedia.org/wiki/Glucuronide#:~:text=Glucuronic%20acid%20is%20attached%20via,a%20glucuronide%20are%20called%20glucuronidases.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
